Welcome to our dedicated page for HARROW SEC filings (Ticker: HROW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on HARROW's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into HARROW's regulatory disclosures and financial reporting.
HARROW, INC. (HROW) reported a change in its senior finance leadership structure. Effective September 4, 2026, Randall E. Pollard ceased serving as Chief Accounting Officer and principal accounting officer of the company. On the same date, the Board of Directors designated Andrew R. Boll, who is already President and Chief Financial Officer, to also serve as principal accounting officer. The company states that Mr. Boll will not receive any additional compensation for assuming the principal accounting officer role. Biographical and background information about Mr. Boll is incorporated by reference from the Definitive Proxy Statement filed on April 24, 2026.
Harrow, Inc. (HROW) received a notice under Rule 144 relating to the sale of its common stock for the account of Amir Shojaei, Chief Scientific Officer. The notice reports a broker-assisted same-day sale of 11,250 shares of common stock on August 14, 2026 in connection with an employee stock option exercise. The filing lists an aggregate market value of approximately $450,000 for the shares to be sold and notes that 37,487,850 shares of common stock were outstanding. The filer states the notice is being submitted after the sale date due to an inadvertent administrative oversight.
HARROW, INC. executive Amir Shojaei, Chief Scientific Officer, exercised 11,250 stock options for common stock at an exercise price of $35.96 per share on August 14, 2026. The resulting 11,250 common shares were then sold at $40.00 per share in a broker-assisted same-day sale to fund the aggregate exercise price and related transaction costs, and Shojaei did not retain any of the shares acquired upon exercise. After the transaction, 18,750 stock options under this award remain outstanding, with the option originally granted on January 6, 2025 and vesting through January 6, 2029.
Harrow, Inc. reported higher revenue but significantly weaker profitability for the quarter ended June 30, 2026. Total revenues rose to $70.7 million from $63.7 million, driven by Branded products, which grew to $56.1 million, while Compounding revenue declined to $14.6 million. VEVYE revenue more than doubled year over year for the quarter to $29.4 million, and other branded products also increased, partially offset by lower IHEEZO sales.
Despite growth in Branded revenue, profitability deteriorated. Harrow recorded a net loss of $17.3 million for the quarter versus net income of $5.0 million a year earlier, and a six‑month net loss of $44.9 million. Gross margins contracted in both Branded and Compounding segments, while selling, general and administrative expenses increased to $53.3 million for the quarter and research and development rose to $8.1 million, reflecting higher headcount, stock‑based compensation, and clinical activity.
Leverage and cash flows shifted meaningfully. Notes payable, net, increased to $292.4 million after issuing an additional $50.0 million of 8.625% Senior Notes due 2030, contributing to total liabilities of $402.0 million and reducing total stockholders’ equity to $14.8 million. Operating activities used $18.7 million of cash in the first half, compared with positive $18.9 million in the prior‑year period, though cash and cash equivalents rose to $83.9 million. Subsequent to quarter‑end, Harrow agreed to acquire global rights to TYRVAYA for $30.0 million upfront plus up to $70.0 million in milestones.
Harrow, Inc. reported second quarter 2026 revenue of $70.7 million, up 11% year over year, driven by branded products, while GAAP results swung to a net loss of $17.3 million versus income a year ago. Gross margin was 71%, down from 75%.
Key growth drivers were VEVYE with $29.4 million in revenue (approximately 40% sequential and 58% year-over-year growth), IHEEZO with $15.6 million in revenue and record unit demand, and TRIESENCE with record 14,529 units, up 162% year over year. ImprimisRx revenue declined to $14.6 million as units shifted to branded products and certain markets were exited. Adjusted EBITDA was $(1.2) million, down from $17.0 million. Harrow ended June 30, 2026 with $83.9 million in cash and cash equivalents and loans payable of $292.4 million. Management reiterated full-year 2026 guidance of $350–$365 million in revenue and $80–$100 million in Adjusted EBITDA and highlighted the pending TYRVAYA acquisition, expected to contribute more than $30 million in 2027 revenue and be funded from cash on hand.
Harrow, Inc. agreed on August 3, 2026 to acquire from Viatris Inc. the global rights to TYRVAYA varenicline solution nasal spray 0.03 mg, an FDA-approved cholinergic agonist for treating signs and symptoms of dry eye disease. Harrow will acquire assets primarily related to TYRVAYA, including the new drug application and other regulatory approvals, intellectual property, developed technology, inventory, and certain related contracts, and will assume specified liabilities.
As consideration, Harrow will pay $30,000,000 in cash at closing, funded with cash on hand, plus up to $70,000,000 in contingent milestone payments tied to future annual net sales thresholds, subject to a post-closing working capital adjustment. Closing is expected in the second half of 2026, subject to customary conditions and ancillary agreements such as a transition services agreement. Management describes the deal as expanding Harrow’s dry eye franchise alongside VEVYE and other products and states that TYRVAYA is expected to be financially accretive shortly after closing, while cautioning that completion and benefits are subject to various risks.
Opaleye Management Inc., Opaleye, L.P., and James Silverman report beneficial ownership of Harrow, Inc. Common Stock. The Fund directly holds 2,400,000 shares of Common Stock, and each Reporting Person may be deemed to beneficially own these shares through advisory and control relationships.
This position represents 6.44% of Harrow’s Common Stock, based on 37,275,107 shares outstanding as of May 6, 2026shared voting and dispositive power over 2,400,000 shares and no sole voting or dispositive power. They expressly state that the filing does not constitute an admission of beneficial ownership for any purpose.
Sternberg Perry J. reported acquisition or exercise transactions in this Form 4 filing.
Harrow, Inc. director Perry J. Sternberg reported receiving a grant of 5,248 restricted stock units as compensation for services. These RSUs vest in equal quarterly installments over one year from the grant date, with the underlying common shares delivered only after his service with the company ends.
SILVERNAIL LAUREN P reported acquisition or exercise transactions in this Form 4 filing.
Harrow, Inc. director Lauren P. Silvernail received a grant of 5,248 restricted stock units as equity compensation for services. These RSUs vest in equal quarterly installments over one year from the grant date, and the underlying shares will not be delivered, transferred, or sold until service terminates.
Graves Adrienne L reported acquisition or exercise transactions in this Form 4 filing.
Harrow, Inc. director Adrienne L. Graves received a grant of 5,248 Restricted Stock Units as compensation for services. These RSUs vest in equal quarterly installments over one year from the grant date, and the underlying shares will be delivered only upon termination of service and cannot be transferred or sold before then.